<p>马萨诸塞州剑桥，2025 年 12 月 10 日（环球新闻通讯社）—— Fulcrum Therapeutics, Inc. <strong>®</strong>（“Fulcrum”）（纳斯达克：FULC）是一家临床阶段的生物制药公司，专注于开发小分子药物以改善基因定义的罕见疾病患者的生活，今天宣布其之前宣布的公开承销发行的定价，发行 11,851,853 股普通股，公开发行价格为每股 13.50 美元，并且为了某些投资者提供预先融资的认股权证，以购买最多 1,111,193 股普通股，公开发行价格为每个预先融资认股权证 13.499 美元，这代表每股普通股的公开发行价格减去每个预先融资认股权证的 0.001 美元行使价格。Fulcrum 预计此次发行的总收入在扣除承销折扣和佣金及其他发行费用之前，将达到 1.75 亿美元。此外，Fulcrum 已授予承销商一个 30 天的选择权，以相同条款和条件购买最多 1,944,456 股普通股。所有发行的证券均由 Fulcrum 出售。</p>
<p>Fulcrum 目前打算将公开发行中证券销售的净收益主要用于一般企业用途，这可能包括营运资金和资本支出、研究与开发费用，包括资助临床试验、监管提交、商业化、发现及额外的临床前研究与开发其他产品候选者和平台增强、一般和行政费用，以及潜在的收购或投资于补充其业务的公司、技术、产品或资产。</p>
<p>摩根大通、Leerink Partners 和 Cantor 担任此次发行的账簿管理经理。Oppenheimer &amp; Co.和 Truist Securities 也担任此次发行的账簿管理经理。此次发行需满足惯例的成交条件，预计将于 2025 年 12 月 11 日左右完成。</p>
<p>这些证券是由 Fulcrum 根据之前于 2024 年 2 月 27 日向美国证券交易委员会（“SEC”）提交并于 2024 年 4 月 25 日获得 SEC 批准的有效货架注册声明进行发行的。此次发行仅通过书面招股说明书和招股说明书补充进行，这些文件构成注册声明的一部分。与此次发行相关的初步招股说明书补充及相关招股说明书已于 2025 年 12 月 8 日向 SEC 提交，并可在 SEC 的网站 www.sec.gov 上获取，最终的招股说明书补充及相关招股说明书将与最终条款一起提交给 SEC。</p>
<p>当可用时，关于此次发行的最终招股说明书补充及相关招股说明书的副本可从摩根大通证券有限责任公司获取，地址为：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通过电子邮件发送至 prospectus-eq_fi@jpmorgan.com 和 postsalemanualrequests@broadridge.com；Leerink Partners LLC，注意：承销部门，53 State Street，40th Floor，Boston，MA 02109，电话（800）808-7525，分机 6105，或通过电子邮件发送至 syndicate@leerink.com；Cantor Fitzgerald &amp; Co.，邮寄地址：注意：资本市场，110 East 59th Street，New York 10022，或通过电子邮件发送至 prospectus@cantor.com；Oppenheimer &amp; Co. Inc.，注意：承销招股说明书部门，85 Broad Street，26th Floor，New York，NY 10004，或电话（212）667-8055，或通过电子邮件发送至 EquityProspectus@opco.com；或 Truist Securities, Inc.，注意：股本资本市场，740 Battery Ave SE，亚特兰大，乔治亚州 30339，电话（800）685-4786 或通过电子邮件发送至 truistsecurities.prospectus@truist.com。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未进行注册或资格审查，则该等要约、邀请或销售将是非法的。</p>
<p><strong>关于 Fulcrum Therapeutics</strong></p>
<p>Fulcrum Therapeutics 是一家临床阶段的生物制药公司，专注于开发小分子药物，以改善在高未满足医疗需求领域中基因定义的罕见疾病患者的生活。Fulcrum 的主要临床项目是 pociredir，这是一种旨在增加胎儿血红蛋白表达以治疗镰状细胞病的小分子。Fulcrum 利用专有技术识别可以调节基因表达以治疗基因误表达已知根本原因的药物靶点。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”，包括但不限于关于公开发行的完成及其收益使用的声明。所有这些前瞻性声明均基于管理层对未来事件的当前预期，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些前瞻性声明中所列或暗示的结果存在重大和不利的差异。这些风险和不确定性与 Fulcrum 的股价波动、市场条件变化以及与公开发行相关的惯常成交条件的满足有关，以及在上述招股说明书补充文件和注册声明的 “风险因素” 部分中讨论的其他因素，以及 Fulcrum 最近提交的 10-Q 表格季度报告中详细列出的其他风险。不能保证 Fulcrum 能够按照预期条款完成公开发行。本新闻稿中的所有信息均截至发布之日，Fulcrum 不承担更新该信息的义务，即使后续事件导致其观点发生变化，除非法律要求。</p>
<p><strong>联系方式：</strong></p>
<p>Kevin Gardner</p>
<p>LifeSci Advisors, LLC</p>
<p>kgardner@lifesciadvisors.com</p>
<p>617-283-2856</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EQXhOU00zTXpFMU5UTTVJekl4T0RNMU5EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EQXhOU00zTXpFMU5UTTVJekl4T0RNMU5EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png"/></p>

FULC

<p>Fulcrum Therapeutics 宣布其 1.75 亿美元的普通股和预先融资认股权证的公开发行定价。此次发行包括 11,851,853 股，价格为每股 13.50 美元，以及 1,111,193 股的预先融资认股权证，价格为每股 13.499 美元。所得款项将用于公司用途，包括研发和潜在收购。此次发行由摩根大通、Leerink Partners 等管理，预计将于 2025 年 12 月 11 日完成</p>

<p>CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. <strong>®</strong> (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the pricing of its previously announced underwritten public offering of 11,851,853 shares of its common stock at a public offering price of $13.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,111,193 shares of common stock at a public offering price of $13.499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price of each pre-funded warrant. The gross proceeds to Fulcrum from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $175.0 million. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to an additional 1,944,456 shares of its common stock on the same terms and conditions. All of the securities in the offering are to be sold by Fulcrum.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥，2025 年 12 月 10 日（环球新闻通讯社）—— Fulcrum Therapeutics, Inc. <strong>®</strong>（“Fulcrum”）（纳斯达克：FULC）是一家临床阶段的生物制药公司，专注于开发小分子药物以改善基因定义的罕见疾病患者的生活，今天宣布其之前宣布的公开承销发行的定价，发行 11,851,853 股普通股，公开发行价格为每股 13.50 美元，并且为了某些投资者提供预先融资的认股权证，以购买最多 1,111,193 股普通股，公开发行价格为每个预先融资认股权证 13.499 美元，这代表每股普通股的公开发行价格减去每个预先融资认股权证的 0.001 美元行使价格。Fulcrum 预计此次发行的总收入在扣除承销折扣和佣金及其他发行费用之前，将达到 1.75 亿美元。此外，Fulcrum 已授予承销商一个 30 天的选择权，以相同条款和条件购买最多 1,944,456 股普通股。所有发行的证券均由 Fulcrum 出售。</p>
</div><p>Fulcrum currently intends to use the net proceeds from the sale of the securities offered in the public offering primarily for general corporate purposes, which may include working capital and capital expenditures, research and development expenses, including to fund clinical trials, regulatory submissions, commercialization, discovery and additional preclinical research and development of additional product candidates and platform enhancement, general and administrative expenses, and potential acquisitions of, or investments in, companies, technologies, products or assets that complement its business.</p>
<div class="lb-trans"><p>Fulcrum 目前打算将公开发行中证券销售的净收益主要用于一般企业用途，这可能包括营运资金和资本支出、研究与开发费用，包括资助临床试验、监管提交、商业化、发现及额外的临床前研究与开发其他产品候选者和平台增强、一般和行政费用，以及潜在的收购或投资于补充其业务的公司、技术、产品或资产。</p>
</div><p>J.P. Morgan, Leerink Partners, and Cantor are acting as book-running managers for the offering. Oppenheimer &amp; Co. and Truist Securities are also acting as book-running managers for the offering. The offering is subject to the satisfaction of customary closing conditions and expected to close on or about December 11, 2025.</p>
<div class="lb-trans"><p>摩根大通、Leerink Partners 和 Cantor 担任此次发行的账簿管理经理。Oppenheimer &amp; Co.和 Truist Securities 也担任此次发行的账簿管理经理。此次发行需满足惯例的成交条件，预计将于 2025 年 12 月 11 日左右完成。</p>
</div><p>The securities are being offered by Fulcrum pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 27, 2024 and declared effective by the SEC on April 25, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on December 8, 2025 and is available on the SEC’s website at www.sec.gov, and a final prospectus supplement and accompanying prospectus relating to the final terms of the offering will be filed with the SEC.</p>
<div class="lb-trans"><p>这些证券是由 Fulcrum 根据之前于 2024 年 2 月 27 日向美国证券交易委员会（“SEC”）提交并于 2024 年 4 月 25 日获得 SEC 批准的有效货架注册声明进行发行的。此次发行仅通过书面招股说明书和招股说明书补充进行，这些文件构成注册声明的一部分。与此次发行相关的初步招股说明书补充及相关招股说明书已于 2025 年 12 月 8 日向 SEC 提交，并可在 SEC 的网站 www.sec.gov 上获取，最终的招股说明书补充及相关招股说明书将与最终条款一起提交给 SEC。</p>
</div><p>When available, copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorgan.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Cantor Fitzgerald &amp; Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York 10022 or by email at prospectus@cantor.com; Oppenheimer &amp; Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com; or Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, Atlanta, Georgia 30339, by telephone at (800) 685-4786 or by email at truistsecurities.prospectus@truist.com.</p>
<div class="lb-trans"><p>当可用时，关于此次发行的最终招股说明书补充及相关招股说明书的副本可从摩根大通证券有限责任公司获取，地址为：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通过电子邮件发送至 prospectus-eq_fi@jpmorgan.com 和 postsalemanualrequests@broadridge.com；Leerink Partners LLC，注意：承销部门，53 State Street，40th Floor，Boston，MA 02109，电话（800）808-7525，分机 6105，或通过电子邮件发送至 syndicate@leerink.com；Cantor Fitzgerald &amp; Co.，邮寄地址：注意：资本市场，110 East 59th Street，New York 10022，或通过电子邮件发送至 prospectus@cantor.com；Oppenheimer &amp; Co. Inc.，注意：承销招股说明书部门，85 Broad Street，26th Floor，New York，NY 10004，或电话（212）667-8055，或通过电子邮件发送至 EquityProspectus@opco.com；或 Truist Securities, Inc.，注意：股本资本市场，740 Battery Ave SE，亚特兰大，乔治亚州 30339，电话（800）685-4786 或通过电子邮件发送至 truistsecurities.prospectus@truist.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未进行注册或资格审查，则该等要约、邀请或销售将是非法的。</p>
</div><p><strong>About Fulcrum Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Fulcrum Therapeutics</strong></p>
</div><p>Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics 是一家临床阶段的生物制药公司，专注于开发小分子药物，以改善在高未满足医疗需求领域中基因定义的罕见疾病患者的生活。Fulcrum 的主要临床项目是 pociredir，这是一种旨在增加胎儿血红蛋白表达以治疗镰状细胞病的小分子。Fulcrum 利用专有技术识别可以调节基因表达以治疗基因误表达已知根本原因的药物靶点。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion of the public offering and the use of proceeds from the public offering. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Fulcrum’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as the other factors discussed in the “Risk Factors” section in the prospectus supplement and registration statement referenced above and in Fulcrum’s most recently filed Quarterly Report on Form 10-Q, as well as other risks detailed in Fulcrum’s filings with the Securities and Exchange Commission. There can be no assurance that Fulcrum will be able to complete the public offering on the anticipated terms. All information in this press release is as of the date of the release, and Fulcrum undertakes no duty to update this information, even if subsequent events cause its views to change, unless required by law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”，包括但不限于关于公开发行的完成及其收益使用的声明。所有这些前瞻性声明均基于管理层对未来事件的当前预期，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些前瞻性声明中所列或暗示的结果存在重大和不利的差异。这些风险和不确定性与 Fulcrum 的股价波动、市场条件变化以及与公开发行相关的惯常成交条件的满足有关，以及在上述招股说明书补充文件和注册声明的 “风险因素” 部分中讨论的其他因素，以及 Fulcrum 最近提交的 10-Q 表格季度报告中详细列出的其他风险。不能保证 Fulcrum 能够按照预期条款完成公开发行。本新闻稿中的所有信息均截至发布之日，Fulcrum 不承担更新该信息的义务，即使后续事件导致其观点发生变化，除非法律要求。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Kevin Gardner</p>
<div class="lb-trans"><p>Kevin Gardner</p>
</div><p>LifeSci Advisors, LLC</p>
<div class="lb-trans"><p>LifeSci Advisors, LLC</p>
</div><p>kgardner@lifesciadvisors.com</p>
<div class="lb-trans"><p>kgardner@lifesciadvisors.com</p>
</div><p>617-283-2856</p>
<div class="lb-trans"><p>617-283-2856</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EQXhOU00zTXpFMU5UTTVJekl4T0RNMU5EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMDAxNSM3MzE1NTM5IzIxODM1NDI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png"/></p>

Fulcrum Therapeutics 宣布扩大规模的 1.75 亿美元普通股和预付款认股权证公开发行的定价 | FULC 股票新闻